On Wednesday, Truist Securities adjusted its stock price target for Willis Towers Watson (NASDAQ:WTW), a global advisory and solutions company, increasing it from $335.00 to $365.00. This change comes in the wake of the company's recent announcement that it will sell its TRANZACT direct-to-consumer Medicare Advantage distribution operation to private equity firms GTCR and Recognize for $632 million.
The transaction is anticipated to be finalized by the end of the year. As part of the deal, Willis Towers Watson is expected to record impairment charges in the third quarter ranging from $1.6 billion to $2.1 billion. Despite these charges, Truist Securities has maintained a Buy rating on the company's shares.
The new price target of $365 represents a 4.0% yield on the company's projected 2025 free cash flow. According to the analyst from Truist Securities, this target is still higher than the average yield of 3.5% found among Willis Towers Watson's peers. The firm attributes this optimistic valuation to the rising valuations within the sector.
The sale of the TRANZACT operation is a significant move for Willis Towers Watson, as it refocuses its business and capital allocation. The deal with GTCR and Recognize is expected to influence the company's financials, with the recognition of substantial impairment charges in the current quarter.
Investors and market watchers will be keeping an eye on Willis Towers Watson as it progresses towards the completion of this divestiture by the year's end. The company's stock price may reflect the market's reaction to both the sale and the adjusted price target in the upcoming trading sessions.
In other recent news, Willis Towers Watson has been the focus of several recent developments. The company has agreed to sell its Tranzact business to private equity firm GTCR and technology services investment platform Recognize for $632.4 million. This move is expected to simplify Willis Towers Watson's operations and financial reporting, according to Keefe, Bruyette, & Woods, which has maintained an Outperform rating for the company.
Meanwhile, Roth/MKM has increased its price target for Willis Towers Watson to $345.00 from $315.00, maintaining a Buy rating on the stock. This adjustment followed the Tranzact divestiture announcement, and Roth/MKM expressed confidence in the management's decision, believing it aligns with Willis Towers Watson's strategy to enhance shareholder value. The firm considers Willis Towers Watson the best-value property and casualty broker in the market.
In contrast, Barclays has initiated coverage on Willis Towers Watson with an Underweight rating due to concerns about the company's ability to meet its organic growth estimates. Despite these varying perspectives, these recent developments suggest a significant shift in Willis Towers Watson's business structure.
InvestingPro Insights
Willis Towers Watson's recent strategic move to sell its TRANZACT operation aligns with several positive indicators highlighted by InvestingPro data. The company's market cap of $30.53 billion and a strong revenue of $9.686 billion in the last twelve months underscore its significant market presence.
InvestingPro Tips reveal that WTW has maintained dividend payments for 22 consecutive years and has raised its dividend for 7 consecutive years, demonstrating a commitment to shareholder returns. This consistency in dividend policy could be particularly attractive to investors in light of the recent TRANZACT sale and the company's refocusing efforts.
The company's stock is currently trading near its 52-week high, with a robust 46.31% price total return over the past year. This performance, coupled with the fact that 10 analysts have revised their earnings upwards for the upcoming period, suggests a positive outlook that aligns with Truist Securities' optimistic price target adjustment.
For investors seeking a deeper understanding of Willis Towers Watson's financial health and future prospects, InvestingPro offers additional insights with 8 more tips available on their platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.